StockDecksJohnson & Johnson
Healthcare · Drug Manufacturers - General
The four fundamentals ratings
Each rating is built from the measures listed beneath it. Values are the latest reported figures; the rating beside each one is how that measure scores on our −100 to +100 scale.
Debt levels, liquidity and how solid the balance sheet looks.
| Debt to equity | 0.58 × | -96 |
| Buybacks vs new shares | Bought back $6.0B of its own shares last year (≈1.0% of its market value) | +27 |
Margins, and the returns being earned on the capital employed.
| Gross margin | 67.8 % | +80 |
| Operating margin | 25.1 % | +70 |
| Net margin | 16.2 % | +56 |
| Gross profit / assets | 32.1 % | +24 |
| Asset turnover | 0.47 × | — |
| Profit vs cash flow | $26.8B profit, generated $24.5B cash | -15 |
The direction and pace of revenue and earnings.
| Revenue growth (YoY) | 5.9 % | +6 |
| Earnings growth (YoY) | -96 % | -99 |
| Earnings growth (Q) | -95.9 % | -99 |
What you pay relative to what the business actually delivers.
| P/E (trailing) | 39.4 × | -37 |
| Forward P/E | 22.35 × | -7 |
| PEG ratio | 2.8 × | -78 |
| Price/Book | 7.36 × | -78 |
| Price/Sales | 6.3 × | -12 |
| EV/EBITDA | 18.74 × | -17 |
Key figures
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market cap | $625.7B |
| Dividend yield | 2.11% |
| Payout ratio | 60.72% |
| Beta | 0.21 |
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech.
See the live card
The figures above were captured on 20 October 2026. Open JNJ in StockDecks for the current numbers, plus the four ratings it doesn't show here — Hype, Analyst Upside, Trend Signals and Insider Track — all free.
Premium adds the Full Score and Custom Score, which combine these fundamentals with the other ratings into a single number.